Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV
combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir [NFV],
indinavir [IDV], ritonavir soft gel capsules [RTV sgc], or saquinavir soft gel capsules [SQV
sgc]).
Anti-HIV therapy with 3 or 4 drugs is currently the recommended approach for treating HIV
infections. Doctors need to know the best dosages of certain drugs when they are given in
combination. This study will measure the blood levels of APV alone, APV combined with EFV,
and APV/EFV plus a second PI in healthy volunteers. It will study the safety and tolerance of
these drugs.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)